Literature DB >> 22814904

An overview of tubulin inhibitors that interact with the colchicine binding site.

Yan Lu1, Jianjun Chen, Min Xiao, Wei Li, Duane D Miller.   

Abstract

Tubulin dynamics is a promising target for new chemotherapeutic agents. The colchicine binding site is one of the most important pockets for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. A large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. CBSIs have been modified as to chemical structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers. CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin. The present review is a synopsis of compounds that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814904      PMCID: PMC3667160          DOI: 10.1007/s11095-012-0828-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  153 in total

1.  Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.

Authors:  Gregory E Agoston; Jamshed H Shah; Theresa M Lavallee; Xiaoguo Zhan; Victor S Pribluda; Anthony M Treston
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

2.  BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.

Authors:  Chih-Bo Hu; Ching-Ping Chen; Teng-Kuang Yeh; Jen-Shin Song; Chi-Yen Chang; Jiunn-Jye Chuu; Fei-Feng Tung; Pei-Yin Ho; Tung-Wei Chen; Chi-Hung Lin; Min-Hsien Wang; Kai-Yen Chang; Chen-Lung Huang; Heng-Liang Lin; Wen-Tai Li; Der-Ren Hwang; Jyh-Haur Chern; Ling-Ling Hwang; Jang-Yang Chang; Yu-Sheng Chao; Chiung-Tong Chen
Journal:  Cancer Sci       Date:  2010-10-12       Impact factor: 6.716

3.  Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure.

Authors:  Yuri Yamazaki; Koji Tanaka; Benjamin Nicholson; Gordafaried Deyanat-Yazdi; Barbara Potts; Tomoko Yoshida; Akiko Oda; Takayoshi Kitagawa; Sumie Orikasa; Yoshiaki Kiso; Hiroyuki Yasui; Miki Akamatsu; Takumi Chinen; Takeo Usui; Yuki Shinozaki; Fumika Yakushiji; Brian R Miller; Saskia Neuteboom; Michael Palladino; Kaneo Kanoh; George Kenneth Lloyd; Yoshio Hayashi
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

4.  4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.

Authors:  Tao Liu; Rong Cui; Jing Chen; Jun Zhang; Qiaojun He; Bo Yang; Yongzhou Hu
Journal:  Arch Pharm (Weinheim)       Date:  2011-02-02       Impact factor: 3.751

5.  Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.

Authors:  M Cushman; H M He; J A Katzenellenbogen; R K Varma; E Hamel; C M Lin; S Ram; Y P Sachdeva
Journal:  J Med Chem       Date:  1997-07-18       Impact factor: 7.446

6.  A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Authors:  G J Rustin; G Shreeves; P D Nathan; A Gaya; T S Ganesan; D Wang; J Boxall; L Poupard; D J Chaplin; M R L Stratford; J Balkissoon; M Zweifel
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

7.  Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors.

Authors:  Jing-Ping Liou; Zi-Yi Wu; Ching-Chuan Kuo; Chi-Yen Chang; Pei-Yi Lu; Chi-Ming Chen; Hsing-Pang Hsieh; Jang-Yang Chang
Journal:  J Med Chem       Date:  2008-06-28       Impact factor: 7.446

8.  Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.

Authors:  B Shan; J C Medina; E Santha; W P Frankmoelle; T C Chou; R M Learned; M R Narbut; D Stott; P Wu; J C Jaen; T Rosen; P B Timmermans; H Beckmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.

Authors:  Jing-Ping Liou; Kuo-Shun Hsu; Ching-Chuan Kuo; Chi-Yen Chang; Jang-Yang Chang
Journal:  J Pharmacol Exp Ther       Date:  2007-07-27       Impact factor: 4.030

10.  Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.

Authors:  C de Ines; D Leynadier; I Barasoain; V Peyrot; P Garcia; C Briand; G A Rener; C Temple
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

View more
  157 in total

1.  Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.

Authors:  Ravi Kumar Vyas Devambatla; Wei Li; Nilesh Zaware; Shruti Choudhary; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem Lett       Date:  2017-05-27       Impact factor: 2.823

2.  Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Authors:  Souvik Banerjee; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Shanshan Deng; Lei Yang; Guo-Bo Li; Jinliang Yang; Stephen W White; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2018-02-12       Impact factor: 7.446

3.  Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent.

Authors:  Weiguo Xiang; Shruti Choudhary; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2018-04-04       Impact factor: 3.641

4.  Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives.

Authors:  Ebrahim Saeedian Moghadam; Ernest Hamel; Zahra Shahsavari; Mohsen Amini
Journal:  Daru       Date:  2019-03-20       Impact factor: 3.117

Review 5.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

6.  Identification of diaryl 5-amino-1,2,4-oxadiazoles as tubulin inhibitors: the special case of 3-(2-fluorophenyl)-5-(4-methoxyphenyl)amino-1,2,4-oxadiazole.

Authors:  Andrei A Gakh; Andrey V Sosnov; Mikhail Krasavin; Tam Luong Nguyen; Ernest Hamel
Journal:  Bioorg Med Chem Lett       Date:  2013-01-11       Impact factor: 2.823

7.  Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives.

Authors:  Javad Ghanaat; Mohammad A Khalilzadeh; Daryoush Zareyee
Journal:  Mol Divers       Date:  2020-02-17       Impact factor: 2.943

8.  Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization.

Authors:  Haichan Niu; Tracy E Strecker; Jeni L Gerberich; James W Campbell; Debabrata Saha; Deboprosad Mondal; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Med Chem       Date:  2019-05-24       Impact factor: 7.446

Review 9.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs.

Authors:  Darcy Bates; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

10.  Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design.

Authors:  Cristina C Rohena; Nakul S Telang; Chenxiao Da; April L Risinger; James A Sikorski; Glen E Kellogg; John T Gupton; Susan L Mooberry
Journal:  Mol Pharmacol       Date:  2015-12-11       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.